Fostemsavir Learning Journey
Welcome to your learning journey detailing aspects to consider in the management of Multi drug resistant (MDR) individuals living with HIV. We also highlight the role of low CD4 T cells and broad importance of gp120 in driving HIV immunopathogenesis. The core characteristics of Fostemsavir are also described in a large population of study participants with data up to 5 years.
Please click on one of the four options below to launch your journey.
NP-GBL-HVX-WCNT-230002 April 2023
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
